Necessary cookies make a website usable by enabling basic functions such as page navigation and access to secure areas of the website. These cookies cannot be switched off in Parexel’s systems. They are usually only set in response to actions made by you, which amount to a request for services, such as setting your privacy preferences, logging in or completing forms. You may be able to decline these cookies through your browser, but necessary parts of the website will then not work. These cookies do not store any personally identifiable information.
|Cookie pxlCookieConsent||Expiry Session||Domain staging.tannwestlake.com||Company Parexel||Purpose Necessary|
|DescriptionStores your cookie consent session for our site. It contains no information other than whether you have opted in or out for each cookie level.|
|Cookie wordpress_test_cookie||Expiry Session||Domain staging.tannwestlake.com||Company Parexel||Purpose Necessary|
|DescriptionTests that the browser accepts cookies.|
PRMT5 Inhibitor PRT543 Displays Potent Antitumor Activity in U2AF1S34F and RBM10LOF Spliceosome-Mutant Non-Small Cell Lung Cancer In Vitro and In Vivo
Jack Carter, Koichi Ito, Venkat Thodima, Monisha Sivakumar, Michael Hulse, Joseph Rager, Komali Vykuntam, Neha Bhagwat, Kris Vaddi, Bruce Ruggeri, Peggy Scherle
Poster presented at the
Oral presentation presented at the AACR Annual Meeting 2022, April 8-13, 2022, New Orleans, LA, USA
This is an electronic reproduction of an oral presentation presented at the AACR Annual Meeting 2022, April 8-13, 2022, in New Orleans, LA, USA. All copyrights remain those of the copyright holder. This page will not be available after May 13, 2022.